Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral ...
Zelicapavir is an investigational, orally administered small molecule designed to treat infections caused by respiratory syncytial virus (RSV). It is a key asset in Enanta's virology pipeline, aimed at providing a potent therapeutic option for patients suffering from RSV, an area with significant unmet medical need.
Price Range: N/A (Clinical-stage development)
Pain Points: Lack of effective, targeted treatments for severe respiratory syncytial virus infections.
Solutions: Provides a novel, oral antiviral intervention that directly targets the virus to reduce symptoms and disease progression.
Target Users: Healthcare providers, hospitals, and patients suffering from severe RSV infections.
Supply Chain
Internal discovery and lead optimizationContract manufacturing organizations (CMOs) for clinical drug supplyClinical research organizations (CROs) for trial management
MAVIRET (glecaprevir/pibrentasvir) is a combination therapy developed by Enanta and licensed to Abbott/AbbVie. It utilizes Enanta's proprietary NS3/4A protease inhibitor (glecaprevir) to combat various genotypes of the hepatitis C virus, offering a highly effective cure for millions of patients.
Pain Points: The global health crisis of chronic Hepatitis C infection, which leads to liver damage and failure.
Solutions: A highly effective, pangenotypic treatment that has helped cure over a million patients worldwide.
Target Users: Patients diagnosed with Hepatitis C and healthcare providers specializing in hepatology and infectious diseases.
Supply Chain
Enanta Pharmaceuticals (Discovery/Licensing)AbbVie (Global manufacturing, clinical development, and commercialization)Global pharmaceutical distribution network
Part of Enanta's immunology pipeline, these programs focus on small molecule inhibition of KIT, a receptor tyrosine kinase, to modulate immune responses and address inflammatory conditions.
Pain Points: Unmet needs in chronic inflammatory conditions where current treatments provide insufficient symptom relief.
Solutions: Highly specific inhibition of immune-activating pathways to reduce inflammation at the source.
Target Users: Immunologists and patients with chronic inflammatory skin or systemic conditions.
Supply Chain
Internal R&D chemistryLaboratory analytical servicesContract research partners
This program aims to develop small molecule inhibitors of STAT6, a critical signaling protein in the type 2 immune response, to provide novel therapeutic avenues for various inflammatory diseases.
Price Range: N/A (Development phase)
Pain Points: Current standard-of-care treatments for allergic or inflammatory conditions have limited efficacy or significant side effects.
Solutions: Precision targeting of the STAT6 pathway to suppress hyperactive inflammatory responses.
Target Users: Patients with inflammatory immune conditions.
Supply Chain
Internal drug discovery unitsExternal preclinical testing facilities
Enanta is leveraging its expertise in small molecule chemistry to target MRGPRX2, a receptor involved in mast cell activation, to develop treatments for pruritic and inflammatory skin diseases.
Price Range: N/A (Early research/development)
Pain Points: Chronic itching and localized inflammation related to overactive mast cells.
Solutions: Inhibition of MRGPRX2 to block the release of inflammatory mediators.
Target Users: Dermatology specialists and patients suffering from chronic skin inflammation/itching.
Supply Chain
Internal medicinal chemistry teamBiotech research infrastructure
AbbVie Inc.NYSE:ABBVThermo Fisher Scientific Inc. (Patheon CDMO)NYSE:TMOUnnamed CDMOs (Clinical-Stage Drug Substance & Drug Product Manufacturers)Unnamed CROs (Clinical Research Organizations)Laboratory Reagent & Equipment Suppliers (Thermo Fisher, MilliporeSigma, Agilent, etc.)Unnamed APCIs / Fine Chemical SuppliersUnnamed Excipient & Packaging Suppliers
Downstream
5
AbbVie Inc.NYSE:ABBVOMERS Life Sciences (OMERS Capital Partners)National Institute of Allergy and Infectious Diseases (NIAID)Shionogi & Co., Ltd.TSE:4507Novartis AGNYSE:NVS
